Tenet Healthcare Corporation (THC) Stock Price & Analysis
Tenet Healthcare Corporation (THC) closed at USD 270.63 on Thursday, October 22, 2026, up 0.56% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 269.13; the Oct 22, 2026 session ranged USD 264.77–272.88 on volume of 590,183 shares. Market capitalization is $21.79B, with a 52-week range of USD 157.58–283.05 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:26 UTC.
Also available as compact Markdown for AI agents: nexqual.com/THC.md
Key facts (THC)
- Last four reported quarters (through Jun 30, 2026): revenue $21.8B, net income $3.17B (14.6% margin), free cash flow $3.02B (SEC filings).
- Valuation: P/E 6.9x (avg 5.5x at the last 3 fiscal year-ends), EV/EBITDA 6.0x, net debt $10.9B.
- 2 of 80 tracked superinvestors hold THC (13F, Q2 2026): 0 new, 1 added, 0 reduced, 1 unchanged.
- Analysts: Buy (mean 1.96 on a 1–5 scale) (23 analysts), mean target USD 286.41 (range 260–315).
- Total return with dividends: 1Y +30.8% vs S&P 500 +14.9%; 5Y +283.2% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 4.68, revenue estimate $5.51B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (THC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $19.5B | $19.2B | $20.6B | $20.7B | $21.3B | $21.8B |
| Operating income | $2.87B | $2.33B | $2.51B | $5.96B | $3.51B | $4.54B |
| Net income | $1.48B | $1.00B | $1.31B | $4.06B | $2.37B | $3.17B |
| EPS (diluted) | $8.42 | $3.79 | $5.71 | $32.70 | $15.49 | — |
| Free cash flow | $910M | $321M | $1.62B | $1.12B | $2.53B | $3.02B |
| Operating margin | 14.7% | 12.2% | 12.2% | 28.8% | 16.5% | 20.8% |
| Net margin | 7.6% | 5.2% | 6.4% | 19.7% | 11.1% | 14.6% |
| Revenue growth | +10.5% | -1.6% | +7.2% | +0.5% | +3.1% | — |
| Cash + short-term investments | $2.36B | $858M | $1.23B | $3.02B | $2.88B | — |
| Total debt | $15.8B | $15.2B | $15.1B | $13.3B | $13.3B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (THC)
P/E 6.9x · P/S 1.0x · EV/EBITDA 6.0x · EV/Sales 1.5x · P/FCF 7.2x · P/B 4.7x · FCF yield 13.87% · Earnings yield 14.57% · Buyback yield (TTM) 7.58% · Net debt $10.9B · EV $32.7B
P/E at fiscal year-ends: Dec 2025 7.6x, Dec 2024 3.0x, Dec 2023 6.0x.
Superinvestors (SEC 13F-HR, Q2 2026) (THC)
2 of 80 tracked investors hold THC. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | <0.01% | $1.7M | Added +68.6% |
| Bill Nygren | Oakmark Funds | <0.01% | $449K | Unchanged |
Analysts (THC)
Consensus Buy (mean 1.96 on a 1–5 scale), 23 analysts; mean target USD 286.41 (low 260, high 315).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-16 | Guggenheim | Target raised | Buy | $283 → $307 |
| 2026-09-23 | BMO Capital | Initiated | Market Perform | $265 |
| 2026-09-18 | Leerink Partners | Maintained | Outperform | $309 |
| 2026-08-03 | Wells Fargo | Target raised | Overweight | $231 → $281 |
| 2026-07-28 | Truist Securities | Target raised | Buy | $270 → $290 |
| 2026-07-28 | Baird | Target raised | Neutral | $210 → $280 |
| 2026-07-28 | Guggenheim | Target raised | Buy | $242 → $283 |
| 2026-07-27 | UBS | Target raised | Buy | $288 → $308 |
| 2026-07-27 | TD Cowen | Target raised | Buy | $233 → $263 |
| 2026-07-27 | Morgan Stanley | Target raised | Overweight | $254 → $274 |
| 2026-07-27 | RBC Capital | Target raised | Outperform | $236 → $283 |
| 2026-07-24 | Barclays | Target raised | Overweight | $240 → $271 |
Total return (dividends reinvested) (THC)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +30.8% | +283.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +30.9% | +30.7% |
| Volatility (annualized) | 42.2% | 44.6% |
| Max drawdown | -34.1% (Mar 2026→Jun 2026) | -58.9% (Feb 2022→Oct 2022) |
THC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $4.68 | $4.09 | +14.2% | $5.51B | 20 |
| Next quarter (ends Dec 2026) | $5.67 | $4.73 | +20.1% | $5.77B | 20 |
| Current fiscal year (ends Dec 2026) | $21.23 | $17.85 | +18.9% | $22.42B | 21 |
| Next fiscal year (ends Dec 2027) | $21.09 | $17.79 | +18.5% | $22.52B | 21 |
Key Statistics (as of October 23, 2026 at 09:26 UTC)
| Price | USD 270.63 |
|---|---|
| Change | ▲ 0.56% (up) |
| Previous Close | USD 269.13 |
| Open | USD 269.62 |
| Day Range | USD 264.77 – 272.88 |
| 52-Week Range | USD 157.58 – 283.05 |
| Volume | 590,183 shares |
| Market Cap | $21.79B |
| Exchange | NYQ |
Technical Analysis (THC)
Nexqual's technical model rates THC "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 09:26 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 55.71 (neutral) |
| vs SMA50 | Above (USD 264.85) |
| MACD | 2.97 (positive) |
Analyst Ratings (THC)
Wall Street analysts rate THC "Buy" based on 23 analysts, with a mean price target of USD 286.41 (range USD 260–315), per Nexqual as of October 23, 2026 at 09:26 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 23 |
| Mean Target | USD 286.41 |
| High Target | USD 315 |
| Low Target | USD 260 |
| Buy / Hold / Sell | 19 / 4 / 0 |
Earnings (THC)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 4.68 |
| Revenue Estimate | $5.51B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 6.12 vs est 4.26 ▲ beat |
| 2026-03-31 | USD 4.82 vs est 4.17 ▲ beat |
| 2025-12-31 | USD 4.7 vs est 4.07 ▲ beat |
| 2025-09-30 | USD 3.7 vs est 3.35 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financials & Fundamentals (THC)
| Total Revenue | $21.81B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +6.80% |
| Gross Margin | +41.66% |
| Operating Margin | +18.16% |
| Profit Margin | +10.27% |
| ROE | +37.34% |
| Debt / Equity | 1.52 |
| Current Ratio | 1.41 |
| Total Cash | $2.17B |
| Total Debt | $13.25B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $3.02B (13.9% of revenue) |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financial Health Score (THC)
Nexqual rates Tenet Healthcare Corporation's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:26 UTC.
| Growth | Mixed — Revenue +3.1% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 42%, operating 18% (last 12 months) |
| Balance Sheet | Weak — $2.17B cash and investments vs $13.1B debt (Jun 2026, SEC) |
| Cash Flow | Solid — FCF $3.02B (last 4 quarters to Jun 2026, SEC), 14% margin |
| Efficiency | Strong — ROE 37%, ROA 8.3% |
Ownership (THC)
| Insider Ownership | +0.97% |
|---|---|
| Institutional Ownership | +101.91% |
| Shares Outstanding | 80.52M |
| Float | 79.68M |
| Short % of Float | +2.66% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Leadership (THC)
Tenet Healthcare Corporation is led by Saumya Sutaria, Chairman & CEO, per Nexqual as of October 23, 2026 at 09:26 UTC.
| Chairman & CEO | Saumya Sutaria |
|---|---|
| Executive VP & CFO | Sun K. Park |
| Executive VP & Chief Operating Officer | Lisa Y. Foo |
| Vice President of Investor Relations | William McDowell |
| Executive Vice President of Corporate Development | Michael T. Maloney |
Major Backers & Investors (THC)
Notable institutional backers of Tenet Healthcare Corporation include Price (T.Rowe) Associates Inc, Boston Partners, FMR, LLC, according to Nexqual as of October 23, 2026 at 09:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Price (T.Rowe) Associates Inc | 9.88% |
| Boston Partners | 5.51% |
| FMR, LLC | 4.96% |
| TR PRICE-Price (T.Rowe) U.S. Value Equity Trust | 3.53% |
| T. Rowe Price | 3.34% |
| Glenview Capital Management, Llc | 2.78% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.86% |
| Vanguard Group | 10.1% |
| State Street | 3.42% |
| Geode Capital | 2.34% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EHC | Encompass Health Corporation | USD 126.01 | ▲ 4.6% |
| DVA | DaVita Inc. | USD 186.1 | ▲ 5.25% |
| FMS | Fresenius Medical Care AG | USD 22.23 | ▲ 3.11% |
| UHS | Universal Health Services, Inc. | USD 188.13 | ▲ 2.88% |
| ENSG | The Ensign Group, Inc. | USD 178.35 | ▲ 2.88% |
| PACS | PACS Group, Inc. | USD 47.5 | ▲ 1.58% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:26 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt